Along with Ambros Therapeutics’ merger with Werewolf Therapeutics, the combined company will raise $150 million in a private placement. Ambros is in Phase 3 testing with a drug developed for treating a type of pain that does not respond to currently available medicines, including opioids.
The post Ambros Therapeutics’ Path for Pain Drug Goes Through Reverse Merger With Werewolf appeared first on MedCity News.
